.......we should easily be in the $1.75 - $1.80 range and position to approach $2.00......but, I'll take $1.60 for now..........GLTA longs............
Spelling may not be 65's strong suit, but I believe he/she had good intentions, and yes, meant Pfizer and Roche................
King..........good point..........I had forgotten about that...........hey, who knows where all of this could lead.........
More about Otsuka....In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology", and then bought Astex in 2013 and Avanir in 2014 for $3.54 billion......think about it.
Otsuka Holdings Co., Ltd., abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964. As of 2012, OPC employed 40,000 people worldwide. The company focuses on pharmaceuticals related to nutrition (or "nutraceuticals"). The company is also known for the popular sports drink Pocari Sweat and the best-selling energy drink Oronamin C. Otsuka Pharmaceutical also developed Abilify (aripiprazole), an approved drug treatment for schizophrenia and bipolar disorder, which they claim has a better side effect profile compared with other antipsychotic drugs. As of 2013, annual sales of Abilify were over ~US$8 billion a year, making it the highest grossing drug worldwide.
OPC joined the Tokyo Stock Exchange through an initial public offering (IPO) on December 15, 2010, at which time OPC was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company. The IPO debuted at US$2.4 billion, making it the largest for a pharmaceutical company up to that time.
In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology".
In September 2013, Otsuka Holdings announced it had agreed to acquire Astex Pharmaceuticals for close to $900 million. In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion.
Astex (an Otsuka Pharmaceutical Company) and Galena co-authored the below Abstract being published at 2015 ASCO, plus they are "presenting" at 2015 ASCO and the 2015 EHA (European Hematology Association) meeting in Vienna, Austria; same place Galena is presenting GALE-401......coincidence....I think not. Perhaps Otasku is the "sleeper" who will buy GALE, just like they did Astex.......think about it !!!
Analytical validation of Bond Oracle HER2 IHC system for identifying low to intermediate HER2-expressing breast cancer in NeuVax PRESENT phase III clinical trial.
2015 ASCO Annual Meeting
J Clin Oncol 33, 2015 (suppl; abstr e11609)
Author(s): Amit K Jain, Sonia Kumar, Gavin S. Choy, Desiree Hollemon, Elizabeth Ann Mittendorf; Leica Biosystems, Danvers, MA; Astex Pharmaceuticals Inc, Burlingame, CA; Galena Biopharma, Portland, OR; The University of Texas MD Anderson Cancer Center, Houston, TX.
Agreed.............and if 3 out of 3 go our way, we could easily be in the $3 - $5 price range.....IMHO............
Up, up and away................
Must work if they are presenting it. If it didn't work, they'd just bite the bullet, do a Press Release stating so and get it out of the way.....IMHO............Also, go for approval in Europe while the FDA moves like a snail here in the US........again IMHO........
PORTLAND, Ore., May 22, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (GALE), a biopharmaceucal company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that data from the Company's Phase 2 clinical trial of GALE-401, or Anagrelide Controlled Release, will be presented at the upcoming European Hematology Association 20th Congress in Vienna, Austria. Details of the poster presentation are as follows:
Abstract #: P671
Title: Phase 2 Study of a Novel Controlled-Release Formulation of Anagrelide (GALE-401) in Subjects with Myeloproliferative Neoplasm (MPN)-Related Thrombocytosis
Session Title: Myeloproliferative neoplasms - Clinical 2
Date: Saturday, June 13, 2015
Time: 5:15 p.m. to 6:45 p.m. local time
Location: Poster area (Hall C)
About GALE-401 (Anagrelide Controlled Release)
GALE-401 (Anagrelide Controlled Release) contains the active ingredient anagrelide. The currently available immediate release formulation (Agrylin(R) or anagrelide IR) is approved by the FDA for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. Adverse events associated with anagrelide IR, such as nausea, diarrhea, abdominal pain, palpitations, tachycardia, and headache, may be dose and plasma concentration dependent. Reducing the maximum plasma concentration (Cmax) is expected to reduce side effects, but preserve efficacy. GALE-401 is a reformulated, controlled release version of anagrelide. In Phase 1 studies in healthy volunteers, GALE-401 was shown to significantly reduce the Cmax while maintaining plasma exposure to reduce platelet counts. Thus, GALE-401 may reduce treatment-related adverse events while maintaining effective therapeutic levels to decrease platelet production
......they are going to explode soon with NeuVax Phase III interim data.............plus GALE301 & GALE 401 data out soon; likely as ASCO next week................
Why can't GALE do PR like this.........they need to get off their dead #$%$..............
Prima BioMed Announces A$15 Million Investment From US Healthcare Investor RidgebackMarketwired(Thu, May 14)
Prima BioMed Announces Japanese CollaborationMarketwired(Mon, May 11)
Prima Biomed to Prioritize Immuno-Oncology Programs Targeting Immune Checkpoint LAG-3Marketwired(Mon, Mar 2)
Prima BioMed to Receive Financial Milestone Payment From GSKMarketwired(Wed, Jan 28)
Prima BioMed Receives $777K R&D Tax Incentive RefundMarketwired(Tue, Jan 20)
is up dramatically today on ovarian drug Phase II trial news..........GALE needs to get their XXXX together before the competition beats them to market............
Nap...I totally agree with your comment on Lento; he just doesn't have it......I am giving Schwartz the benefit of the doubt and feel Einhorn's past relationship(s) with the SEC may pay dividends, plus he appears to be well--connected in the industry...........I guess we'll know when the court decisions are announced.
You are probably aware of this, but abstracts with an "e" prefix (such as this one), will be published, but not presented, at ASCO as noted below on the abstract. Not sure why, but that's what it says.
(Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2015 ASCO Annual Meeting but not presented at the Meeting, can be found online only.